CD274 and non-small cell lung carcinoma: Indeed, PET imaging studies of PD-L1 with [89Zr]Zr-DFO-atezolizumab (FDA approved anti-PD-L1 antibody) demonstrated a strong correlation between PD-L1 expression and clinical outcome in NSCLC patients [107].